Skip to main content

Impact Lab Group to Acquire HeartGenetics

NEW YORK — Italian oncology genetics company Impact Lab Group said on Tuesday that it has agreed to acquire HeartGenetics, a developer of bioinformatic software and personalized genetic tests.

Cantanhede, Portugal-based HeartGenetics offers a range of genetic tests and services including ones for general wellness, cardiovascular conditions including hereditary thrombophilia and hypertrophic cardiomyopathy, and pharmacogenetics. Impact said the acquisition will broaden its portfolio of test panels and expand its presence in Spain, Portugal, and South America.

Under the terms of the deal, HeartGenetics will continue to operate under its name and serve its customers in Portugal, Brazil, Netherlands, and Spain, with the opportunity to begin sales in Italy. HeartGenetics Cofounder and CEO Ana Teresa Freitas will continue to lead the company.

"HeartGenetics proved to have the skills to develop new genetic tests and software taking into consideration the whole research and development process, [which includes] gene and variant selection, disease risk models, machine learning-based reports, and product information materials," Impact Lab Group CEO Vittorio Grazioli said in a statement. "These skills will be crucial for the future development of affordable genetic testing and will be instrumental in the development of new tests for the preventive medicine market."

In April 2019, Impact Lab acquired Toma Advanced Biomedical Assays Services Lab, which offers cytogenetics, molecular biology, and prenatal diagnostics.